Analgesic use may decrease postmenopausal estrogen levels

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 4
Volume 19
Issue 4

Postmenopausal women who regularly use painkillers have lower estrogen levels, which could lead to a decreased risk of breast or ovarian cancer.

Postmenopausal women who regularly use painkillers have lower estrogen levels, which could lead to a decreased risk of breast or ovarian cancer, according to researchers at Boston's Brigham and Women's Hospital and Harvard Medical School (Cancer Epidemiol Biomarkers Prev online, March 23, 2010).

The investigators looked at the link between the use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen and concentrations of estrogens and androgens among 740 postmenopausal women who participated in the Nurses' Health Study. The frequency of all analgesic use was inversely associated with estradiol, free estradiol, estrone sulfate, and the ratio of estradiol to testosterone. The average estradiol levels were 10.5% lower among women who regularly used aspirin or non-aspirin NSAIDs. Free estradiol levels were 10.6% lower and estrone sulfate levels were 11.1% lower among regular users of aspirin.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Related Content